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Abstract
Introduction: Rotavirus vaccine efficacy ranges from .90% in high socio-economic settings (SES) to 50% in low SES. With
the imminent introduction of rotavirus vaccine in low SES countries, understanding reasons for reduced efficacy in these
settings could identify strategies to improve vaccine performance.
Methods: We developed a mathematical model to predict rotavirus vaccine efficacy in high, middle and low SES based on
data specific for each setting on incidence, protection conferred by natural infection and immune response to vaccination.
We then examined factors affecting efficacy.
Results: Vaccination was predicted to prevent 93%, 86% and 51% of severe rotavirus gastroenteritis in high, middle and low
SES, respectively. Also predicted was that vaccines are most effective against severe disease and efficacy declines with age
in low but not high SES. Reduced immunogenicity of vaccination and reduced protection conferred by natural infection are
the main factors that compromise efficacy in low SES.
Discussion: The continued risk of severe disease in non-primary natural infections in low SES is a key factor underpinning
reduced efficacy of rotavirus vaccines. Predicted efficacy was remarkably consistent with observed clinical trial results from
different SES, validating the model. The phenomenon of reduced vaccine efficacy can be predicted by intrinsic
immunological and epidemiological factors of low SES populations. Modifying aspects of the vaccine (e.g. improving
immunogenicity in low SES) and vaccination program (e.g. additional doses) may bring improvements.
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Introduction
Diarrhea causes an estimated 1.3 million childhood deaths per
year, of which approximately one-third are a result of rotavirus
infections. [1,2] The WHO in 2009 issued a global recommen-
dation for the inclusion of rotavirus vaccines into routine
immunization programs, based on results from successful clinical
trials from Asia and Africa. [3,4,5,6] These vaccines have great
potential to prevent the severe morbidity and mortality from
rotavirus, but studies consistently demonstrate a gradient of
reduced efficacy in low socio-economic settings (SES) where the
burden of severe rotavirus disease, particularly mortality, is
greatest. [7] Clinical trials and observational studies of oral
rotavirus vaccines performed in infants in high income settings
demonstrated vaccine efficacy (VE) exceeding 90%. [8,9,10,11,12]
In middle income settings of Latin America, South Africa and
Vietnam,VE ranged from 72 to 83%, [5,13] while in low income
settings in Asia and Africa, VE ranged from 39 to 49%. [4,5,6]
These same patterns are apparent for both currently licensed
vaccines (single-strain RotarixH (GlaxoSmithKline Biologicals) and
pentavalent RotateqH (Merck & Co) referred to henceforth as RV1
and RV5, respectively). Understanding the biological basis for this
poorer performance may be crucial for maximizing the impact of
current vaccines and for guiding the development of new ones.
With all existing live oral vaccines against enteric infections
(including typhoid, cholera and oral polio), the immune response
and efficacy are diminished amongst certain populations living in
developing countries. [4,5,6,14,15,16] While the exact reasons for
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this phenomenon are unclear, a range of hypotheses has been
proposed. These can be broadly categorized as (1) factors leading
to a poor immune response to natural infection, (2) reduced
immunogenicity of the vaccines, and (3) very high incidence rate of
infection that overwhelms immunity from vaccination. Over-
growth of bacteria in the small bowel (‘tropical enteropathy’), [17]
concomitant infections including helminths, [18] micronutrient
deficiency [19] and nutritional status are specific factors that have
all been associated with diminished immune response to live oral
vaccination, and would also affect immunity to natural infection.
Furthermore, the greater diversity of rotavirus strains circulating in
many developing countries may lead to weaker natural and
vaccine-derived immunity. [20] In very young infants in low SES,
greater levels of maternal antibody acquired trans-placentally or
from breast milk may serve to neutralize vaccine virus so as to
reduce replication and antigen load and thereby decrease the
immunogenicity. [21] Identifying whether these factors can
explain the reduced vaccine efficacy observed in low SES, and
which factors are most important, can help to prioritize future
research aimed at improving vaccine performance.
We aimed to interpret rotavirus clinical trial and field
effectiveness observations in a range of SES using a mathematical
model and to illustrate how these different factors may contribute
to reduced efficacy of vaccination. We used a dynamic mathe-
matical model that incorporates age structure and the natural
history of rotavirus infection and immunity. Three scenarios were
constructed to reflect the protection conferred by natural infection
and vaccination, immunogenicity of vaccines, and disease in-
cidence in high, middle, and low SES. Based on our findings, we
identify and discuss potential strategies to improve the perfor-
mance of rotavirus vaccines in low SES.
Methods
Model
We developed and analyzed a deterministic mathematical
model of rotavirus transmission and disease (see Figure S1 and
Equations S1).; [22] The model is dynamic and incorporates age
structure and the natural history of rotavirus infection and
immunity. Individuals are born into a class where they are
protected by maternal antibody. Immunity wanes at a constant
rate, after which individuals move into the first susceptible class.
Immunity to rotavirus infection is complex and incomplete,
reflecting what is known about the natural history of rotavirus; we
included four susceptible (S1–S4) and infected (I1–I4) classes.
Individuals move from Sn to In at an age-specific force of infection
(li). Once infected, a proportion (jn) develops symptomatic
rotavirus gastroenteritis (RV-GE), wn of which are severe (defined
as a score $11 on the Vesikari scale). [23] These proportions vary
depending on the order of infection (primary, secondary, tertiary
or quaternary) and SES. Following infection, a proportion an
enters the next susceptible class, while 1-an develops long-term
immunity. Only symptomatic individuals are assumed to contrib-
ute to transmission, and all episodes are assumed to be of the same
duration (1/cn = 7 days).
Scenarios
Three scenarios were constructed to reflect the protection
conferred by natural infection and vaccination, immunogenicity of
vaccines, and disease incidence in high, middle and low SES.
Protection from natural infection and vaccination. The
protection conferred by natural infection has been estimated by
Velazquez et al. [24] in Mexico and more recently by Gladstone
et al. [25] in South India. Both studies demonstrated increased
protection against infection with each subsequent exposure to
rotavirus. However, while the proportion of infected infants with
symptomatic disease and the proportion of them with severe
disease decreased following each subsequent infection in Mexico,
no clear pattern was observed in South India. No studies of this
type have been performed in higher income settings, so we used
the Mexico data to represent natural history in high and middle
SES and the South India data to represent low SES.
Rotavirus immunization is by live oral vaccination, and
mechanistically is believed to mimic immunity from natural
infection. We assumed that each dose of vaccine acts like a single
infection, without causing symptomatic disease. Two doses of
vaccine, given at 2 and 4 months of age, were assumed to confer
protection equivalent to primary and secondary infection.
Immunogenicity of vaccines. We assumed that only a pro-
portion of children who received a given dose of vaccine are
protected, [26] as determined by the proportion who seroconvert.
The rates of seroconversion for high, middle, and low SES were
based on a literature review of 24 immunogenicity studies of RV1,
where seroconversion was defined as GMC .20 U/mL. [27] We
explored the plausible range in predicted VE that may result from
variation in immunogenicity by also running the model at the
highest and lowest seroconversion rate reported from studies from
each SES. In this framework, vaccination is ‘‘all-or nothing’’, in
the sense that a dose either confers protection or not. However, the
two doses mimic first and second natural infections in the sense
that vaccination, like prior infection, mitigates against disease:
a greater degree of mitigation is associated with each consecutive
vaccine dose (as is the case for each natural infection).
Incidence. Based on the natural history data, the high,
middle, and low SES models were fit by adjusting q (the infectivity
parameter) to age-specific incidence data from cohort studies in
England [28], Mexico [24], and India [25] to represent the three
settings (Figures S2). The best-fit models were determined by
minimizing the root-mean-square deviation (RMSD) in Berkeley-
Madonna (Berkeley, CA, USA). In all settings, it was assumed that
the population size was stable over the period of the study (births
equal to deaths), but that birth and death rates were inversely
associated with SES (life expectancy of 80, 75 and 60 years
corresponding to birth rates of 12.5, 13.3, and 16.7 live births per
1,000 per year in high, middle and low SES, respectively). We also
investigated a higher birthrate of 25.0 births per 1,000 per year in
low SES, which is more realistic for India. As a simplifying
assumption, we assumed that all deaths occurred in the adult age
class (25 years and older). Levels of maternal immunity were
assumed to be greater in low SES (Table 1). [21,27,29].
The best fit models, with SES-specific parameters, were then
used to analyze vaccine efficacy as described below.
Efficacy
Efficacy was defined as the proportion of cases prevented per
vaccinated child. In this framework, vaccine efficacy is complex: it
is a function of age-specific incidence by order of infection
(primary, secondary, etc), the proportion symptomatic (dn) and
severe (wn) at the n
th infection, as well as the ‘take’ of the vaccine.
For these reasons, it was not possible to solve analytically for the
age-specific efficacy. In order to isolate the direct effect of
vaccination, we fixed the age- and setting-specific force of infection
to the equilibrium pre-vaccination value derived from the model
fitting. After fitting the dynamic model, the force of infection was
fixed using the parameters of the best fit model, and the model was
run to endemic. The model was run for 60 years to achieve
endemic equilibrium (which is achieved quickly when the force of
infection is fixed) and stable age structure before introducing
Modeling Rotavirus Vaccine Efficacy
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vaccination. Efficacy was calculated as one minus the incidence at
equilibrium in a fully vaccinated cohort divided by the incidence
in an unvaccinated cohort. This approach is used to compare
incidence in vaccinated and unvaccinated groups without allowing
vaccination to affect the transmission dynamics, representing a trial
scenario.
Efficacy in the 6 to 23 month age group is presented as the main
outcome measure to facilitate comparison with the age group that
was primarily followed for clinical outcomes in vaccine trials. We
estimated absolute reductions as cases prevented per cohort of
1000 vaccinated children.
The incremental effect of the immune response to natural
infection and vaccination, the immunogenicity of vaccines, and the
underlying incidence rate on efficacy was determined by changing
each parameter in a stepwise fashion. Starting with the baseline
model with low SES parameters, we changed the proportion who
seroconvert (c) from 0.63 (low) to 0.74 (middle) then to 0.86 (high);
next we changed the natural history parameters (ax, jx and wx)
from the values from Velazquez et al [24] to Gladstone et al [25];
finally, the force of infection was changed by altering q from qlow to
qmid to qhigh (Table 1). In addition, we also considered the potential
value of a third dose of vaccine given at 6 months of age in low
SES, assuming that protection from a third dose is the same as
a third natural infection.
Results
In the 6 to 23 month age group, the model generated vaccine
efficacy (VE) estimates against severe RV-GE of 93%, 86% and
51% in high, middle and low SES, respectively (Table 2). Under
the higher birth rate scenario (25 per 1000 per year) in low SES,
our estimate of VE was marginally reduced (by 2%). When
considering the range of seroconversion values in the literature, we
predicted VE to range from 79% to 99% in high SES, 77% to
93% in middle SES and 47% to 53% in low SES. Against all RV-
GE, VE was 66%, 58% and 53%, respectively. VE decreased in
low SES in 3 year olds and was negligible in 4 year olds. In
contrast, VE did not decrease amongst older age groups in middle
or high income settings (Figure 1).
From 6 to 23 months of age, 71 cases of severe RV-GE per year
were estimated to be prevented for every 1000 vaccinated children
in low SES, while 63 cases per 1000 vaccinated were prevented in
high SES (Table 2). However, in older age groups, this pattern was
reversed, with larger gains in higher income settings. This is
a function of both the younger age distribution of rotavirus and
lower efficacy of the vaccine in low SES. By age 5 years,
vaccination of 1000 children would prevent 139, 202, and 89
severe cases in high, middle, and low SES, respectively.
Starting from a baseline of 51% efficacy among 6 to 23 month-
olds in low SES, efficacy was projected to improve to 58% and
65%, respectively, if immunogenicity of vaccination was increased
to levels from middle and high income countries (Figure 2 and
Figure S3). The rest of the gap in efficacy (to 93% in high income
settings) was a result of differences in the protection conferred by
natural infection. Underlying incidence had no long-term impact
on vaccine efficacy. A third dose of vaccine given at 6 months of
age was predicted to increase efficacy from 51 to 60%.
Figure 3 illustrates the relationship between age-specific vaccine
efficacy estimates and the proportion of infections that were either
primary or secondary (as projected by the model). In high and
middle SES, VE remained steady as the proportion of infections
that were primary or secondary decreased with age. In low SES,
VE fell with this proportion.
Discussion
This modeling study demonstrates that the phenomenon of
reduced rotavirus vaccine efficacy in low SES can be explained by
intrinsic immunological and epidemiological factors. While natural
rotavirus infections protect against subsequent infections across
a range of SES, a key difference is that, unlike in middle and high
SES, in low SES the proportion of infections that result in
symptomatic disease does not rapidly decline with each subsequent
infection; a similar proportion of primary or secondary infections
Table 1. Model parameters.
High Middle Low Symbol
Duration of maternal immunity (weeks) [21,29] 13 13 26 1/m
Life expectancy (years) 80 75 60 1/d
Duration of infectiousness (days) [23] 7 7 7 1/c
Relative risk of infection following
First infection 0.62 0.62 0.61 a1
Second infection 0.37 0.37 0.48 a2
Third infection 0.37 0.37 0.33 a3
Proportion of infections with any GE (severe GE)
First infection 0.47 (0.28) 0.47 (0.28) 0.30 (0.17) j1 (w1)
Second infection 0.24 (0.19) 0.24 (0.19) 0.28 (0.23) j2 (w2)
Third infection 0.32 (0) 0.32 (0) 0.18 (0.24) j3 (w3)
Fourth infection 0.20 (0) 0.20 (0) 0.21 (0.18) j4 (w4)
Source [24] [24] [25]
Proportion who seroconvert to vaccination [27] 0.86 (0.67 to 0.98) 0.74 (0.63 to 0.86) 0.63 (0.58 to 0.67) c
Infectivity parameter* Fitted 0.235781 0.604687 2.25781 q
*The infectivity parameter q represents the proportion of infectious contacts (i.e. when a susceptible and infectious individual come into contact) that result in
transmission, multiplied by a constant factor by which the contact rate is assumed to scale across settings.
doi:10.1371/journal.pone.0041720.t001
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result in severe rotavirus disease when compared with tertiary and
subsequent infections. Thus, if vaccination mimics primary and/or
secondary natural infection(s), subsequent infections and illnesses
will not be adequately protected against, resulting in lower VE and
shorter apparent duration of protection in low SES where
subsequent infections occur at a high rate and continue to be
severe.
A number of model VE outputs, predicted based on the natural
history and immunogenicity data, are consistent with clinical trial
findings, which is reassuring regarding the validity of our
assumptions. First and foremost, the model predicts higher VE
with increasing SES. Efficacy against severe RV-GE was similar in
our model (93%) as it was for RV1 and RV5 in clinical trials and
observational studied in high SES, where VE of greater than 90%
was observed. [30,31] Similar effectiveness estimates have been
found in post-marketing surveillance studies. [8,32,33,34] Our
estimate of 86% efficacy against severe RV-GE in middle income
countries is again consistent with trials across Latin America
(83%), in South Africa (77%), and Vietnam (72%), and
observational studies of effectiveness in El Salvador (76%) and
Brazil (76%). [4,5,13,35,36] Our VE estimate of 51% in low SES
populations approximates the VE of 49% in Malawi, 43% in
Bangladesh, and 39% observed in three sub-Saharan African
countries. [4,5,6] Our main results relied on the mean serocon-
version rates by SES. However, in limited sensitivity analysis, we
demonstrated that the range of seroconversion rates observed in
immunogenicity studies may also explain some of the variation in
VE from clinical trials.
Secondly, the model projects VE against severe RV-GE to be
approximately 25% greater than against all RV-GE in middle and
high SES. This is remarkably consistent with trial data from high
SES. [31] However, the model does not predict this differential
efficacy in low SES because the proportion of cases that are severe
is similar with each subsequent infection. The limited data from
these settings indicates that the gap between severe and all RV-GE
VE may be smaller. [4,5,6] If future data on all-severity RV-GE in
low SES support this prediction, it will give further support to the
notion that the mechanism of vaccine action is to mimic natural
infection, as well as helping to understand the potential impact of
the vaccine on transmission in these settings.
Third, the model predicts and provides an explanation for what
appears to be ‘waning’ of VE in low SES but not high SES
populations, which has been observed in the clinical trial data. In 3
African settings, efficacy of RV5 against severe RV-GE was
estimated to be 64% in the first year of life, falling to 20% in the
second year [6]; smaller, but nonetheless important declines have
been observed in El Salvador, Nicaragua and Brazil, [35,37,38]
Figure 1. Predicted age-specific efficacy on severe RV-GE and all RV-GE. A) Vaccine efficacy: Severe RV-GE. B) Vaccine efficacy: All RV-GE.
doi:10.1371/journal.pone.0041720.g001
Table 2. Predicted vaccine efficacy and severe cases
prevented per 1000 vaccinated children in high-, middle-
and low-socio economic settings.
Vaccine efficacy Cases prevented
0 to 4 yrs 6 m to 23 m 0 to 4 yrs 6 m to 23 m
Severe RV-GE
High 0.91 0.93 139 63
Middle 0.81 0.86 202 133
Low 0.41 0.51 89 71
All RV-GE
High 0.63 0.66 392 167
Middle 0.57 0.58 660 374
Low 0.44 0.53 537 410
*Results are presented in these two age groups to facilitate comparison with
clinical trials (6–23 m) and population impact assessments (0 to 4 yrs).
doi:10.1371/journal.pone.0041720.t002
Figure 2. Predicted vaccine efficacy on severe rotavirus
gastroenteritis incidence in 6 to 23 month-olds. Step-wise
influence of improving the underlying natural history of protection,
immunogenicity of vaccines, and baseline disease incidence. The gray
shaded area on the baseline bar indicates the potential incremental
increase in VE from a third dose given at 6 months of age.
doi:10.1371/journal.pone.0041720.g002
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though it should be noted that studies have generally not been
powered to estimate effectiveness in second year of life and
beyond. The model does not fully capture how quickly VE falls; in
clinical trials, VE declined by the second year of life and in the
model, it fell in the third. However, waning – traditionally defined
as loss of immunity over time – is not an influential feature of the
model (as waning occurs on a scale of .40 years). Even without
loss of immunity, VE as measured by clinical trials or cohort
studies, can, in some circumstances, fall with increasing age. If
vaccination reduces the force of infection and provides only partial
protection for vaccinated individuals, proportionally more cases
will occur in older age groups amongst vaccinated than un-
vaccinated individuals. [39] Still, a better model fit could perhaps
be achieved by explicitly incorporating loss of immunity, in effect
representing local versus systemic immunity. However, the data
needed to parameterize such a model for a range of SES are not
available.
Because immunity to rotavirus is incrementally-acquired, our
model proposes a different mechanism to explain reduced VE in
older children. In the model, each dose of the vaccine mimics
a natural infection. With a two-dose course, all children who
respond to vaccination in higher SES are protected against severe
disease as all severe disease is thought to occur as a result of the
first two infections. In low SES, the mechanism of the vaccine is
the same and higher order infections do confer additional
protection against infection [24], but severe disease continues to
occur in third, fourth and subsequent infections. These higher
order infections make up a larger proportion of infections as
children age, and are not protected against by vaccination, so in
older children VE appears to ‘wane’. This is an important
observation in that it suggests that additional vaccinations, for
example a dose given with measles vaccination in the EPI schedule
at 9 or 12 months, may improve performance among children in
low SES, although the level of protection conferred by such
schedules needs to be clinically evaluated.
We have assumed that the immune response to natural infection
and vaccination, immunogenicity of vaccines, and background
rotavirus incidence are independent factors, and this may be an
important limitation. For example, part of the reason that live oral
vaccines may be less effective is due to concomitant infections of
the gut, as had been posited for OPV. [16] Rotavirus and other
concomitant infections will both be more common in low SES/
high incidence settings, where vaccines also appear to be less
immunogenic. [27] As we have demonstrated, background
rotavirus incidence itself may affect the impact of the vaccine
program, but not VE directly; concomitant infections could still
explain lower VE by interfering with both the immune response to
vaccination and immunogenicity of vaccines.
We have also assumed that the severity of disease is dependent
on the number of previous infections (and decreases with each
subsequent one). However, it remains possible that severity is age-
dependent. If, for instance, under 1 year-olds are more susceptible
to severe disease regardless of the number of previous infections,
just delaying age at infection will reduce severe disease. Age and
number of previous infections may confound each other, but due
to limitations in available data it is difficult to disentangle these
factors. It is important to note that the younger age distribution of
infection in low SES may at least partly explain the discrepancy in
natural immunity between mid/high and low SES. Research
directed at this issue may help to elucidate the extent to which
simply delaying time to infection could result in a reduction in
severe disease.
We are not aware of any robust data on mixing patterns and
contact structures for either middle or low income settings, so we
assumed mixing was proportional to age-specific patterns for
Great Britain from a large European study. [40] These data are
unlikely to represent mixing patterns in either Mexico or India.
We account for this, at least in part, by allowing the parameter q to
vary. q represents the probability of transmission given a contact
between a susceptible and infectious person. However, q may also
be interpreted as a composite of infectiousness and frequency of
contact, so a higher q ultimately represents a higher force of
infection, which could result from greater infectiousness or more
frequent contacts. Further studies are needed to elucidate mixing
patterns for middle and low income settings.
Underpinning our results are the findings from the Indian
natural history study that severe disease continues to occur in third
and subsequent infections, whereas in Mexico severe cases are
principally restricted to primary infection. A host of reasons for
this discrepancy are possible. Exposure to higher doses of virus
may occur in low SES, which could overcome immunity from
previous infections. Greater strain diversity and more limited
cross-protective immunity may also play a role. In addition to the
mechanism we have modeled, immunity from both natural
infection and vaccination may wane (in the ‘‘traditional’’ sense),
whereby protective antibody is lost over time in children in low
SES.
We have taken data from the UK, Mexico and India to be
a general reference for the diverse range of epidemiological and
demographic profiles of high, middle and low SES worldwide.
Clearly, this is a simplification as factors such as crowding and
underlying rates of diarrhea differ both between and within
countries such as India, resulting in lower VE. [16] Despite this
simplification, we were able to match many of the observations of
rotavirus vaccine clinical trials, suggesting that this framework is
Figure 3. Relationship between vaccine efficacy against severe
RV-GE and the proportion of infections that are primary or
secondary, by age group. In high (black points) and middle (green
points) SES VE remains stable across age groups, despite the fact that
the proportions of infections decrease with age, because in these
settings all severe disease is confined to the first two infections. In low
SES, VE falls as the proportion of infections that are primary or
secondary decreases because severe disease continues to occur in
subsequent infections.
doi:10.1371/journal.pone.0041720.g003
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a useful tool for understanding some of the variation in VE across
populations.
Our results help identify potential strategies to improve the
performance of rotavirus vaccines in low SES. The immunoge-
nicity of vaccines is likely to be the most directly modifiable of the
factors investigated. Some vaccines in development, such as the
neonatal 116E strain currently being trialed in India, may be more
immunogenic than currently licensed vaccines. [41] A second
strategy to improve immunogenicity may be directed at the host.
Delaying administration of vaccine from the current 6 and 10
weeks schedule (with RV1) to 10 and 14 weeks [5] may also be an
effective strategy to improve immunogenicity by allowing maternal
antibody to wane for another four weeks [5], though this approach
would have to be weighed against the risks of early natural
infections and the potential risk of intussusception with later
vaccination. A schedule with 3 doses of RV1 given at 6, 10, and 14
weeks might offer the most practical and programmatically feasible
option, given that regulatory and economic considerations are
satisfactorily addressed. We estimate that a third dose of vaccine
may improve VE by approximately 9% in low SES. This finding is
based on the assumption that a third dose of vaccine is as
immunogenic as the first two doses, though there are little
empirical data presently available to support this. [5] Studies are
needed to characterize the immune response and protection
conferred by a third dose of vaccine, and to specifically determine
if immunogenicity is compromised for doses administered at very
young ages as a result of interference from maternal antibody.
In summary, this study demonstrates that even in their current
sub-optimal state, rotavirus vaccines have the potential to sub-
stantially reduce severe diarrheal disease in very young children in
low SES. By identifying and quantifying factors resulting in poorer
vaccine performance in these settings, we are able to propose both
a mechanism by which vaccination provides protection and an
estimate of what can realistically be achieved. Modifying aspects of
the vaccine (e.g. improving immunogenicity in low SES popula-
tions) or vaccination program (e.g. additional doses) may bring
improvements, but in order to fully realize the benefits of the
vaccine, interventions targeted at the host and the broader
epidemiology of disease may be required.
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